The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects

Table 1 Effects of plant sterol ester capsules on plasma lipid profiles and CRP (n = 16)¹

Parameters	Initial Baseline²	Day 7	Day 21	Δ PSE-Placebo	Day 28	Δ PSE-Placebo
Total Cholesterol (mg/dL)	256.0 ± 24.3
Placebo phase		238.4 ± 18.8	239.3 ± 28.3		241.6 ± 27.2
Treatment phase		239.9 ± 29.6	237.4 ± 29.2	-1.9 (-1%)	230.4 ± 22.3	-11.2 (-5%)
LDL (mg/dL)	177.1 ± 22.8
Placebo phase		168.5 ± 22.9	169.8 ± 25.6		169.4 ± 27.0
Treatment phase		170.8 ± 27.7	157.8 ± 22.8 ^{A, a}	-12 (-7%)	163.3 ± 27.0^A	-6.1 (-4%)
HDL (mg/dL)	57.8 ± 19.9
Placebo phase		50.4 ± 13.8	49.1 ± 13.6		51.2 ± 15.4
Treatment phase		50.8 ± 15.5	53.3 ± 16.3^{A, a}	4.2 (9%)	53.5 ± 16.3^a	2.3 (4%)
Triglycerides	125.9 ± 81.4
Placebo phase		116.6 ± 60.8	122.7 ± 89.0		126.5 ± 74.6
Treatment phase		111.4 ± 69.8	121.7 ± 71.4	-1 (< -1%)	115.7 ± 63.6	-10.8 (-9%)
Total Cholesterol/HDL	4.89 ± 1.64
Placebo phase		5.1 ± 1.4	5.2 ± 1.6		5.1 ± 1.6
Treatment phase		5.1 ± 1.5	4.8 ± 1.6^{A, a}	-0.4 (-8%)	4.7 ± 1.4^{A, a}	-0.4 (-8%)
LDL/HDL	3.44 ± 1.28
Placebo phase		3.6 ± 1.3	3.6 ± 1.2		3.7 ± 1.2
Treatment phase		3.7 ± 1.2	3.4 ± 1.2 ^{A, a}	-0.2 (-6%)	3.3 ± 1.2^{A, a}	-0.4 (-10%)
CRP (mg/dL)	0.8 ± 0.5
Placebo phase		0.7 ± 0.4	0.7 ± 0.4		0.7 ± 0.5
Treatment phase		0.8 ± 0.6	0.8 ± 0.5	0.07 (5%)	0.7 ± 0.3	0

¹ Values are means ± SD.
² Initial baseline measurement was done 6 week before the placebo phase. Therefore, the data was not included in any analysis, but are provided as reference information
^A Significantly different from placebo, p < 0.05 (paired t-test)
^a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)

ISSN: 1476-511X